IgY Antibodies Neutralize Beta-Lactamase to Preserve Antibiotics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of antibiotic-resistant bacteria, particularly Extended Spectrum Beta-Lactamases (ESBLs) such as TEM/SHV and CTX-M, poses a significant threat to public health due to their ability to degrade antibiotics, necessitating a more effective treatment alternative.
Innovation Solution
Development of antibodies, specifically IgY antibodies, that target the active site omega loop of beta-lactamase enzymes like TEM-1, either alone or in combination with antibiotics, to inhibit the destruction of beta-lactam antibiotics and treat infections caused by beta-lactamase-producing bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are widely used to treat bacterial infections, then infection treatment effectiveness is improved, but bacterial resistance develops making the antibiotics ineffective
Solution Approach 1:
The patent introduces antibodies as an intermediary substance that mediates between the antibiotic and the beta-lactamase enzyme. The antibodies bind to the omega loop of beta-lactamase, preventing the enzyme from degrading the antibiotic, thereby protecting the antibiotic's effectiveness without directly killing the bacteria.
Solution Approach 2:
The patent extracts and targets a specific functional region (the omega loop) of the beta-lactamase enzyme for antibody binding. By focusing the immune response on this critical enzymatic region, the antibodies specifically inhibit beta-lactamase activity while leaving other bacterial functions intact.
2Reliability
If beta-lactamase enzymes are produced by bacteria to degrade antibiotics, then bacterial survival is improved, but the ability to treat infections is worsened
Solution Approach 1:
Antibodies serve as a mediator that interferes with the beta-lactamase enzyme's ability to degrade antibiotics. The antibodies bind to the omega loop, physically blocking the enzyme's active site and preventing substrate binding, thereby neutralizing the enzyme's harmful function.
Solution Approach 2:
The antibodies provide preliminary anti-action by pre-binding to the beta-lactamase enzyme before it can degrade the antibiotic. This preventive binding blocks the enzyme's catalytic activity in advance, preventing antibiotic degradation before it occurs.
3Ease of operation
If conventional antibiotic treatments are used, then treatment simplicity is maintained, but the emergence of resistant bacterial strains increases
Solution Approach 1:
The patent merges the antibiotic treatment approach with an immune-based approach by combining antibodies with antibiotics. This combination therapy maintains the simplicity of antibiotic use while adding the protective effect of antibodies that prevent beta-lactamase-mediated resistance, creating a synergistic treatment strategy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit the beta-lactamase activity, enhancing the efficacy of antibiotics and providing a therapeutic option against antibiotic-resistant bacteria like TEM-1-producing E. coli.
Implementation Method 1
antibodies (e.g., IgY) directed against the active site omega loop of beta-lactamase enzymes (e.g., TEM (e.g., TEM-1)) can be used alone or in combination with at least one antibiotic (e.g., any beta-lactam antibiotics) to treat bacterial infections
Data Source
AI summary
Provided herein are antibodies, such as immunoglobulins Y (IgY) antibodies that inhibit beta-lactamase activity, e.g., TEM-1 beta-lactamase, as well as related compositions and methods of use thereof to treat infections by lactam-based antibiotic bacteria that produce beta-lactamase that can degrade antibiotics.